| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fa3e8112806b868144b1d7e95d8fa87d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4716 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 |
| filingDate |
2017-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a0fd3541767c5b518641a5985004108
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_995388234b187c850d774c0edd0d0a42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2918edf5d6e7d8162330f7d66f4e79ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e531934328193ae093d1fc4a21940ea3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1618e87d43e0f88453499538762d1b9 |
| publicationDate |
2017-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017188312-A1 |
| titleOfInvention |
Assay method for anti-drug antibodies |
| abstract |
Provided is a method for more simply and accurately measuring ADAs that develop in a patient receiving drug-based, molecular-targeted therapy, or the like. This assay method for ADAs in an assay sample includes the following steps (1) to (4). (1) A step for preparing a specimen which includes an assay sample of ADAs; (2) a step for bringing the specimen prepared in step (1) into contact with a support on which complement C1q, an anti-C3d antibody, or an anti-C1q antibody has been immobilized; (3) a step for bringing a labeled or unlabeled antibody to the aforementioned drug into contact with the solid-phase support produced in step (2); and (4) a step for measuring the quantity of drug-ADA immune complexes bound to complement C1q, the anti-C3d antibody, or the anti-C1q antibody. |
| priorityDate |
2016-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |